12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CMV-IGIV: Phase III start

This month, NIH will begin a double-blind, placebo-controlled U.S. Phase III trial to evaluate IV 100 mg/kg CytoGam in about 800 pregnant women. The trial will screen more than 150,000 pregnant women over 4 years...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >